Last reviewed · How we verify

Paracetamol-Tramadol

Astes · FDA-approved active Small molecule

This combination drug reduces pain through two complementary mechanisms: paracetamol inhibits prostaglandin synthesis in the central nervous system, while tramadol blocks monoamine reuptake and activates opioid receptors.

This combination drug reduces pain through two complementary mechanisms: paracetamol inhibits prostaglandin synthesis in the central nervous system, while tramadol blocks monoamine reuptake and activates opioid receptors. Used for Moderate acute pain, Moderate chronic pain.

At a glance

Generic nameParacetamol-Tramadol
Also known asIntravenous Paracetamol and Tramadol
SponsorAstes
Drug classAnalgesic combination (non-opioid + opioid)
TargetCyclooxygenase (COX), opioid receptors (μ, δ, κ), norepinephrine transporter, serotonin transporter
ModalitySmall molecule
Therapeutic areaPain Management
PhaseFDA-approved

Mechanism of action

Paracetamol (acetaminophen) works primarily as a centrally-acting analgesic and antipyretic by inhibiting cyclooxygenase enzymes and reducing prostaglandin production. Tramadol is a synthetic opioid agonist that also inhibits the reuptake of norepinephrine and serotonin, providing additional analgesic effects through multiple pathways. The combination provides synergistic pain relief for moderate pain conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: